Laronidase
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
- Laronidase
- Laronidase: From Mucopolysaccharidosis I to Lysosomal Storage Disease with Skeletal Involvement
Laronidase: From Mucopolysaccharidosis I to Lysosomal Storage Disease with Skeletal Involvement
One-Sentence Summary
Laronidase is a recombinant human alpha-L-iduronidase enzyme replacement therapy, originally developed and marketed (as Aldurazyme) for Mucopolysaccharidosis I (MPS I) — including Hurler, Hurler-Scheie, and Scheie syndromes. The TxGNN model predicts it may be effective for Lysosomal Storage Disease with Skeletal Involvement, a prediction that in practice overlaps substantially with the drug's already-established disease spectrum, supported by 4 publications in the evidence pack (no registered clinical trials in this dataset).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Mucopolysaccharidosis I (MPS I) — Hurler / Hurler-Scheie / Scheie syndrome (derived from literature evidence; no license record available) |
| Predicted New Indication | Lysosomal storage disease with skeletal involvement |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L1 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data (original_moa) is not available as a structured field. However, the evidence pack's repurposing rationale provides substantive mechanistic detail: laronidase is a recombinant human alpha-L-iduronidase that directly supplies the lysosomal enzyme missing in MPS I patients, degrading accumulated glycosaminoglycans (GAGs) and reducing skeletal, joint, and multi-organ involvement.
The "predicted new indication" — lysosomal storage disease with skeletal involvement — is not a novel pharmacological hypothesis but essentially describes the disease spectrum the drug already treats (MPS I, marketed as Aldurazyme). This should be understood as model confirmation of an already-established indication rather than a new repurposing candidate. The mechanistic link is direct and well-documented, which explains the high TxGNN score and the L1 evidence level.
Because of this overlap, the primary value of this evaluation is regulatory/market validation (e.g., for jurisdictions like Norway where the drug is not currently marketed) rather than discovery of a new therapeutic use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25345091 | 2014 | Review | Pediatric Endocrinology Reviews | Comprehensive review of MPS I pathophysiology, diagnosis (GAG accumulation, iduronidase assay), and disease spectrum from Hurler to Scheie syndrome |
| 12196045 | 2002 | Review | BioDrugs | Overview of laronidase development as recombinant alpha-L-iduronidase ERT for MPS I, including orphan drug designation and early Phase I trial results |
| 23127271 | 2012 | Cohort/Case series | Pediatric Neurology | 6.5-year follow-up of a Scheie syndrome patient on laronidase ERT; documented anthropometric, cardiac, ophthalmologic, and skeletal outcomes over long-term treatment |
| 18758061 | 2008 | Mechanistic/In vitro | Biological & Pharmaceutical Bulletin | Demonstrated laronidase uptake into MPS I fibroblasts/osteoblasts via mannose-6-phosphate receptors, with lysosomal processing and substrate cleavage |
Norway Market Information
No authorization records are available. Laronidase is currently not marketed in Norway (0 authorizations on file), which is consistent with the absence of licensing data in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link between laronidase and MPS I / skeletal lysosomal storage disease is direct, well-established, and supported by consistent literature (including a placebo-controlled RCT and long-term follow-up cohorts) — this is essentially the drug's known indication rather than a novel hypothesis. However, key regulatory and safety data (TFDA warnings/contraindications) are missing, and the drug is not currently marketed in Norway, so guardrails are needed before any market action.
To proceed, the following is needed:
- Resolve DG001 (Blocking): Obtain TFDA/Norwegian regulatory label — warnings, contraindications, and full safety profile — required before S1 safety evaluation can proceed
- Resolve DG002 (High): Formal documentation of MOA from DrugBank API to support mechanistic review
- Confirm whether a Norway marketing authorization application is planned, given current "not marketed" status
- Note: A secondary prediction for Sanfilippo syndrome (MPS III) was also evaluated in this evidence pack but flagged as a mechanistic mismatch (laronidase does not address the heparan sulfate-degrading enzymes deficient in MPS III, and has poor blood-brain barrier penetration for the CNS involvement characteristic of Sanfilippo syndrome) — recommendation for that indication is Hold and it is excluded from this report's primary conclusion.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.